Two analyses supported by the Centers for Disease Control and Prevention’s US influenza data have demonstrated that immunization reduces the risk of hospitalization in children and death in adults
Take a look at this month’s industry headlines including a US FDA approval for RECARBRIO™, positive results for XOFLUZA in children and new ACIP recommendations.
Research presented at ECCMID examining influenza transmission has discovered that a substantial proportion of patients and healthcare workers shed the flu virus before clinical symptoms appear.
The WHO has released a Global Influenza Strategy for 2019–2030 aiming to prevent seasonal flu, prepare for a pandemic situation and control the spread of zoonotic influenza.
Collaborative research efforts with scientists from Janssen, the Scripps Research Institute, the University of Hong Kong, the University of Pennsylvania and more has led to success in creating a promising novel long-lasting llama-derived antibody therapy for influenza.
Roche has announced the FDA approval of Xofluza™, the first and only single-dose oral medicine approved to treat flu.
New research indicates that false negative RIAT results could delay antiviral therapy for half of patients admitted to intensive care units.
A high-fiber diet can boost the immune response and increase survival in mice infected with influenza virus, according to new research.
Take a look at how advancements in genetic engineering has led to advances in vaccine manufacturing, with a divergence from live cell cultures to recombinant production in host cells.
A proof-of-concept study has demonstrated promise for a new vaccine production platform, which was used to build a prototype synthetic flu vaccine.
